Understanding how EZH2 affects treatment resistance in prostate cancer
Official title: A novel role for EZH2 in PARP regulation and PARPi-resistance in prostate cancer
Funded at Northwestern University at Chicago · NIH-10979397 · Data updated 2026-11-12
This study is looking at a protein called EZH2 to understand how it helps prostate cancer resist treatments, with the goal of finding new ways to help men with advanced prostate cancer feel better and respond to new drugs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | July 12, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $582,198 |
| NIH project number | 1R01CA285684-01A1 |
| Project ID | NIH-10979397 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with metastatic prostate cancer who may have limited treatment options.
✕Less likely to help
Patients with early-stage prostate cancer or those not diagnosed with prostate cancer may not benefit from this research.
What this research studies
This research investigates the role of a protein called EZH2 in prostate cancer, particularly how it contributes to resistance against current treatments. By examining the mechanisms of DNA damage and repair, the study aims to identify new therapeutic strategies for men with metastatic prostate cancer. The researchers will analyze the expression levels of EZH2 in cancer cells and explore how this protein influences cancer progression and treatment outcomes. Patients may be involved in trials that test new drugs targeting EZH2 and related pathways.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for prostate cancer, potentially improving survival rates and quality of life for patients.
How similar studies have gone: Previous research has shown promising results in targeting EZH2 and PARP pathways in cancer treatment, indicating potential for success in this approach.
Where this research is happening
-
Northwestern University at Chicago
Chicago, United States Active
Researchers
- Principal investigator: Cao, Qi — Northwestern University at Chicago
- Study coordinator: Cao, Qi
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.